Skip to content

Price / book at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
25.2×+15.2×
Biogen logo
BiogenBIIB
1.4×+0.3×
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
-0.6×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
316.5×+303×
uniQure logo
uniQureQURE
6.8×-10.2×
Precigen logo
PrecigenPGEN
67.7×

Other financials

Income statement

See full
Revenue--100%
Operating income-$43.5M-103%
Net income-$42.4M-97.0%
EPS (diluted)-$0.12-50.0%

Balance sheet

See full
Cash & equivalents$276.6M+137%
Total debt$68.6M+11.2%
Total equity$211.9M+285%
Total assets$300.4M+117%

Cash flow

See full
Operating cash flow-$40.9M-85.6%
CapEx$24.0K-93.7%
Free cash flow-$40.9M-82.6%

Valuation

See full
Market cap$1.97B+351%
Enterprise value$1.76B+368%
P/S263.9×+203×

Profitability

See full
Operating margin-1,774.4%+1,437pp
Net margin-1,738.4%+1,407pp
FCF margin-1,503.6%+621pp

Returns & leverage

See full
Return on equity-97.3%-27.3pp
Debt / equity0.3×-0.8×
Current ratio14×+8.7×

Where this comes from

Calculated from Taysha Gene Therapies, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Taysha Gene Therapies, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Taysha Gene Therapies, Inc.'s price / book?
Taysha Gene Therapies, Inc. (TSHA) reported price / book of 6.1× in Q1 2026.
How has Taysha Gene Therapies, Inc.'s price / book changed year-over-year?
Taysha Gene Therapies, Inc.'s price / book increased by 17.1% year-over-year, from 5.2× to 6.1×.
What is the long-term trend for Taysha Gene Therapies, Inc.'s price / book?
Over 5 years (2020 to 2025), Taysha Gene Therapies, Inc.'s price / book has grown at a 12.4% compound annual growth rate (CAGR), from 3.4× to 6.1×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.